Mumps virus transmission in vaccinated populations,WP 2: short-term and long-term complications of mumps-associated orchitis in vaccinated men * a prospective multicenter cohort trial

Mumps virus transmission in vaccinated populations,WP 2: short-term and long-term complications of mumps-associated orchitis in vaccinated men * a prospective multicenter cohort trial - Complications of mumps-associated orchitis in vaccinated men

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36170

Enrollment

Registered

2011-11-03

Start date

2012-02-09

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mumps orchitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All men of 18 or more prospectively diagnosed with acute uni- or bilateral mumps-associated orchitis in the Netherlands after vaccination are eligible for inclusion.

Exclusion criteria

Exclusion criteria: Exclusion criteria are the inability to ejaculate, the inability to provide written informed consent and risk factors in the medical history for decreased fertility (e.g. cancer, gonadal dysplasia, cryptorchidism etc).

Design outcomes

Primary

Measure	Time frame
Semen quality during initial non-infective phase of mumps orchitis and follow-up during at least 6 months period which can be lengthened if indicated.	—

Secondary

Measure	Time frame
Levels of FSH, LH, testosterone, SHBG and Inhibin B during the abovementioned 6 month period. If possible hormone levels and semen quality after one year.	—

Countries

Netherlands

Outcome results